Off-the-Shelf Chimeric Antigen Receptor T Cells

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

(2020) Ryan Bjordahl et al.   BLOOD

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

(2020) LaQuisa C. Hill et al.   BLOOD

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

(2020) S. Depil et al.   NATURE REVIEWS DRUG DISCOVERY

CRISPR-engineered T cells in patients with refractory cancer

(2020) Edward A. Stadtmauer et al.   SCIENCE

CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy.

(2020) Hans Prenen et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer

(2020) Ghita Chabab et al.   JOURNAL OF LEUKOCYTE BIOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy

(2020) Yuki Kagoya et al.   Cancer Immunology Research

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

(2020) Dana Stenger et al.   BLOOD

Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease

(2020) Tomomi Toubai et al.   BLOOD

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

(2020) Carlos A. Ramos et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering tolerance toward allogeneic CAR-T cells by regulation of MHC surface expression with Human Herpes Virus-8 proteins

(2020) Xiaomei Wang et al.   MOLECULAR THERAPY

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

(2020) Andras Heczey et al.   NATURE MEDICINE

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

(2020) Reuben Benjamin et al.   LANCET

CAR T-cells: costs, comparisons, and commentary

(2019) Annette E. Hay et al.   JOURNAL OF MEDICAL ECONOMICS

Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients

(2019) Tobias Deuse et al.   NATURE BIOTECHNOLOGY

Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods

(2019) Richard P. Harrison et al.   CYTOTHERAPY

Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility

(2019) Huaigeng Xu et al.   Cell Stem Cell

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma

(2019) Cesar Sommer et al.   MOLECULAR THERAPY

New Insights into Graft-Versus-Host Disease and Graft Rejection

(2018) Eric Perkey et al.   Annual Review of Pathology-Mechanisms of Disease

A guide to manufacturing CAR T cell therapies

(2018) Philipp Vormittag et al.   CURRENT OPINION IN BIOTECHNOLOGY

Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells

(2018) Nina Müller et al.   CYTOTHERAPY

Unconventional T Cell Targets for Cancer Immunotherapy

(2018) Dale I. Godfrey et al.   IMMUNITY

Human blood MAIT cell subsets defined using MR1 tetramers

(2018) Nicholas A Gherardin et al.   IMMUNOLOGY AND CELL BIOLOGY

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

(2018) Matthew L Cooper et al.   LEUKEMIA

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

TCR inhibitory molecule as a promising allogeneic NKG2D CAR-t cell approach.

(2018) David Edward Gilham et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia

(2018) John K. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-21 Selectively Protects CD62L+NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy

(2018) Ho Ngai et al.   JOURNAL OF IMMUNOLOGY

Reprogramming human T cell function and specificity with non-viral genome targeting

(2018) Theodore L. Roth et al.   NATURE

Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

(2018) Antonia Rotolo et al.   CANCER CELL

Toward the development of true “off-the-shelf” synthetic T-cell immunotherapy

(2018) Shoichi Iriguchi et al.   CANCER SCIENCE

Potential advantages of CD1-restricted T cell immunotherapy in cancer

(2018) Michela Consonni et al.   MOLECULAR IMMUNOLOGY

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation

(2017) Ifigeneia Tzannou et al.   JOURNAL OF CLINICAL ONCOLOGY

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells

(2017) Daniel T. MacLeod et al.   MOLECULAR THERAPY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

(2017) Germán G Gornalusse et al.   NATURE BIOTECHNOLOGY

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity

(2017) Arnab Ghosh et al.   NATURE MEDICINE

Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy

(2017) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

(2017) Waseem Qasim et al.   Science Translational Medicine

Virus-Specific T Cells for the Immunocompromised Patient

(2017) Amy Houghtelin et al.   Frontiers in Immunology

The Immunology of CD1- and MR1-Restricted T Cells

(2016) Lucia Mori et al.   Annual Review of Immunology

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo

(2016) Gengwen Tian et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical manufacturing of CAR T cells: foundation of a promising therapy

(2016) Xiuyan Wang et al.   Molecular Therapy-Oncolytics

Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies

(2015) Laurent Poirot et al.   CANCER RESEARCH

A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy

(2015) Julien Valton et al.   MOLECULAR THERAPY

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy

(2014) A. Heczey et al.   BLOOD

An Effective Approach to Prevent Immune Rejection of Human ESC-Derived Allografts

(2014) Zhili Rong et al.   Cell Stem Cell

NF- B Modulates Sensitivity to Apoptosis, Proinflammatory and Migratory Potential in Short- versus Long-Term Cultured Human    Lymphocytes

(2014) M. Ferrarini et al.   JOURNAL OF IMMUNOLOGY

The impact of ageing on natural killer cell function and potential consequences for health in older adults

(2013) Jon Hazeldine et al.   AGEING RESEARCH REVIEWS

Depletion of Naïve T Cells From Peripheral Blood Stem Cell Grafts for GVHD Prevention

(2013) Marie Bleakley et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy

(2013) Maria Themeli et al.   NATURE BIOTECHNOLOGY

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

(2012) H. Torikai et al.   BLOOD

The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR

(2012) Li Bai et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

(2012) Elena Provasi et al.   NATURE MEDICINE

Differentiation of human peripheral blood V 1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells

(2011) D. V. Correia et al.   BLOOD

Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells

(2010) M. Dusseaux et al.   BLOOD

Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy

(2010) L Ysebaert et al.   LEUKEMIA

Antitumor Activity of    T Cells Reactive against Cytomegalovirus-Infected Cells in a Mouse Xenograft Tumor Model

(2009) C. Devaud et al.   CANCER RESEARCH

Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

(2009) Liping Song et al.   JOURNAL OF CLINICAL INVESTIGATION

CD16+ γδ T cells mediate antibody dependent cellular cytotoxicity: Potential mechanism in the pathogenesis of multiple sclerosis

(2008) Zhihong Chen et al.   CLINICAL IMMUNOLOGY

Reconstitution of the immune system after hematopoietic stem cell transplantation in humans

(2008) Jan Storek et al.   Seminars in Immunopathology